Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer

This open‐label, phase I dose‐finding study evaluated the gonadotropin‐releasing hormone antagonist, TAK‐385, in Japanese patients with nonmetastatic prostate cancer. In a two‐part design, patients received daily oral TAK‐385 at doses of 320 (loading, day 1)/80 (maintenance, day 2 and thereafter), 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Hiroyoshi, Uemura, Hiroji, Mizokami, Atsushi, Hayashi, Narihiko, Miyoshi, Yasuhide, Nagamori, Satoshi, Enomoto, Yutaka, Akaza, Hideyuki, Asato, Takayuki, Kitagawa, Tadayuki, Suzuki, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792482/
https://www.ncbi.nlm.nih.gov/pubmed/31429205
http://dx.doi.org/10.1002/cam4.2442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792482/
https://www.ncbi.nlm.nih.gov/pubmed/31429205
http://dx.doi.org/10.1002/cam4.2442

Ejemplares similares